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Key Clinical Message
The decision for PJP prophylaxis depends on a physician’s evaluation of multi-
ple variables. The high rate of PJP infection described in this article combined
with the known impaired T-cell function post Bendamustine treatment justifies
considering all patients for PJP prophylaxis when they receive Bendamustine
treatment.
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Introduction
Pneumocystis jiroveci pneumonia (PJP) has been increas-
ingly described as a serious opportunistic infection in HIV-
seronegative patients with malignancy, as a consequence of
immunosuppression from chemotherapy.
The standard method for diagnosing PJP is demonstra-
tion of Pneumocystis in either bronchoalveolar lavage
fluid or induced sputum. Testing with either specimen
has a sensitivity ranging from 80 to 95% [1, 2]. Trimeth-
oprim/sulpfamexazole (TMP/SMX) is the gold standard
for treatment and prophylaxis of PJP.
The death rate due to PJP ranges between 10 and 20%
in patients with HIV [3]. This infection carries a worse
prognosis in the HIV seronegative population with a
mortality rate of 30 to 60%, possibly as a consequence of
late diagnosis and delayed treatment [4].
Bendamustine is an alkylating agent with multiple
unique mechanisms of action. It was first synthesized in
1963 by Ozegowski and Krebs and was available only in
East Germany until 1990. It is increasingly used in the
treatment of chronic lymphocytic leukemia (CLL),
multiple myeloma and non-Hodgkin lymphomas (NHL).
Myelosuppression is a common side effect of Bendamus-
tine with severe T-lymphocyte depletion and increased
risk of opportunistic infections.
We describe four cases of PJP in HIV negative individ-
uals as sequelae of Bendamustine/Rituximab (BR) treat-
ment. The use of PJP prophylaxis has been a routine
practice in patients undergoing treatment with Benda-
mustine.
Case Presentations
Case 1
A 69-year-old male was diagnosed with stage B CLL in June
2011. One year later, cytotoxic therapy was initiated with
Bendamustine (100 mg/m2) on days 1 and 2 and Rituximab
(375 mg/m2) on day 1. He presented on day 13 after the
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third cycle of treatment with dry cough, dyspnea, and a tem-
perature of 38°C. Examination revealed oxygen saturation
(SPO2) of 93% on room air. Fine crackles and wheezes were
audible at both lung bases.
Arterial blood gas (ABG) demonstrated respiratory alka-
losis with hypoxemia. Oxygen partial pressure (PO2) was
9.7 kilopascal (Kpa). Blood cultures did not identify any
organism. Laboratory results showed lymphopenia, ele-
vated C-reactive protein (CRP), and lactate dehydrogenase
(LDH) at 495 U/L (220 upper limit of normal). Chest X-
ray (CXR) was suggestive of PJP with a perihilar and mid-
zone ground glass pattern (Fig. 1). Chest Computed
Tomography (CT) supported the diagnosis of PJP (Fig. 2).
Bronchoscopy was normal, but bronchial washings
were positive for PJP polymerase chain reaction (PCR).
TMP/SMX was initiated at a dosage of 20 mg/kg six
hourly intravenously and continued for 21 days. The
patient improved and was discharged on the prophylactic
dose of TMP/SMX.
Case 2
A 73-year-old male was diagnosed with marginal zone
lymphoma and was treated with Bendamustine (100 mg/
m2) and Rituximab (375 mg/m2) as per standard proto-
col. He presented on day ten after the second cycle of
chemotherapy with fever and productive cough. Examina-
tion revealed tachycardia at 105 beats per minute and
SPO2 of 93% on 40% oxygen. Bronchial breathing and
crackles were heard at the left lower zone.
Investigations showed neutrophil leukocytosis, lymp-
hopenia, renal impairment, high CRP at 192 mg/L and
LDH of 300 U/L. ABG demonstrated hypoxemia with
PO2 of 8.9 Kpa. Lobar consolidation was evident on CXR
(Fig. 3). Echocardiogram revealed mild mitral regurgita-
tion, good left ventricular function, and mild left ventric-
ular hypertrophy.
Despite treatment with Tazocin and Clarithromycin for
a presumed bacterial pneumonia, he remained hypoxic.
Subsequently, he was admitted to ICU for management
of fast atrial fibrillation. Sputum was positive for PJP by
PCR testing. Intravenous TMP/SMX was started on day
six post admission at 20 mg/kg six hourly for 14 days
with complete resolution of the infection.
Figure 1. CXR Showing perihilar and mid-zone ground glass pattern.
Figure 2. CT-Thorax demonstrating perihilar infiltrates consistent
with the diagnosis of PJP.
Figure 3. CXR showing consolidation involving the left lower lobe.
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Case 3
A 68-year-old female was diagnosed with stage IV A fol-
licular B-cell non-Hodgkin lymphoma (FL). She was
started on Bendamustine (90 mg/m2) and Rituximab
(375 mg/m2) as per standard protocol. She developed
fever, dry cough, and dyspnea 14 days post the third cycle
of treatment. Examination revealed fever, hypotension,
and tachypnea. SPO2 was 88 on 40% oxygen. Widespread
wheezes were audible on chest auscultation.
CXR showed bilateral upper and mid zone opacifica-
tion with sparing of both bases (Fig. 4). Laboratory inves-
tigations revealed lymphopenia, high CRP and LDH of
1090 U/L. The patient received Tazocin without any ben-
eficial effect. Twenty-four hours later, she deteriorated
further and remained hypotensive, breathless, and hyp-
oxic. She was transferred to ICU, required intubation and
ventilation. PJP was identified by PCR testing in the
bronchoalveolar lavage.
Treatment with intravenous TMP/SMX was started
on day three of admission at 20 mg/kg six hourly and
continued for 15 days. She remained on mechanical
ventilation for 33 days. Eventually, she was weaned suc-
cessfully from the ventilator and made a complete
recovery.
Case 4
A 71-year-old female with a diagnosis of CLL was treated
with Bendamustine (100 mg/m2) and Rituximab
(375 mg/m2) as per standard protocol. She presented to
the emergency department on day ten after the first cycle
with fever, rigors and vomiting for 2 days. Physical exam-
ination revealed a high-grade temperature of 39°C, tachy-
cardia and tachypnea. Her SPO2 was 98% on room air.
No other abnormalities were identified on examination.
Laboratory investigations showed lymphopenia, renal
impairment, elevated CRP of 42 mg/L and LDH of
305 U/L. ABG on 40% oxygen showed hypoxemia with
PO2 of 8.2 Kpa. CXR was suggestive of PJP with large
volume perihilar infiltration (Fig. 5).
The patient was subsequently commenced on intrave-
nous TMP/SMX at 20 mg/kg eight hourly and she was
transferred to ICU as she was hypotensive and hypox-
emic. Bronchoscopy was deferred as the patient was too
unstable. Echocardiogram was normal with good LV
function. She developed paroxysmal fast atrial fibrillation,
which was managed with Amiodarone infusion. She made
an excellent clinical recovery after 14 days of intravenous
TMP/SMX with complete resolution of the radiological
signs.
Discussion
In patients with hematological malignancies or solid
tumors receiving chemotherapy or high-dose steroid ther-
apy, clinicians should be vigilant to the possibility of PJP
and consider the need for prophylaxis [5].
Like HIV patients, lymphopenia may place cancer
patients at increased risk of opportunistic infections such
as PJP. However, in contrast to the HIV population, there
has not been agreement regarding PJP prophylaxis in
HIV seronegative patients receiving immunosuppressive
therapies. In a meta-analysis of randomized controlled tri-
Figure 4. CXR showing bilateral upper and mid zone opacification
with sparing of the bases. Figure 5. CXR revealing perihilar infiltration.
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als of PJP prophylaxis in immunocompromised patients
without HIV, the meta-analysis concludes that PJP pro-
phylaxis is indicated when the risk of PJP is higher than
3.5% in adults [6].
All patients described received Bendamustine and
Rituximab. Rituximab has rarely been associated with
PJP. In the initial trials of Rituximab with combination
chemotherapy, over 3000 patients were treated without
any cases of PJP described [7]. Case reports have
described Pneumocystis pneumonia post Rituximab treat-
ment, but the rate of infection is low [8–14].
Bendamustine has the potential to induce a reduction in
CD4 lymphocyte counts causing a severe T-lymphocyte-med-
iated immunosuppression. Bendamustine is a recognized risk
for opportunistic infection, including PJP [15–18]. It may
result in grade 3 to 4 lymphopenia in 74% of patients and
thus, a recent article has recommended bimonthly monitor-
ing of CD4 T-helper cells with initiation of PJP prophylaxis
in patients with counts less than 200/lL [19].
A review of randomized controlled trials (RCTs) found
that prophylaxis with TMP/SMX significantly reduced the
occurrence of PJP by more than 90% [6]. Preventive
treatment was not associated with an increased risk of
adverse events. Given the low rate of adverse events,
which include nausea, skin rash, and myelosuppression,
prophylaxis should be considered for patients at risk.
According to reports, gastrointestinal symptoms and skin
reactions, each occurs in about 3.5% of patients [20]. The
incidence and severity of the adverse reactions are gener-
ally dose dependent. Hematological cytopenias are the
most serious side effect, reportedly occurring in less than
0.5% of patients [21]. No differences between once daily
versus thrice weekly TMP/SMX were seen [18, 22].
The described patient cases provide evidence that PJP
can develop in patients without significant evidence of
neutropenia and infection and can occur early in treat-
ment. Bendamustine was received by 67 patients between
November 2009 and October 2014 in our practice, pri-
marily for low-grade lymphoproliferative disorders. We
describe four cases of PJP of 39 patients, who received
Bendamustine before PJP prophylaxis was introduced in
August 2012. Twenty-eight patients have received Benda-
mustine since the introduction of PJP prophylaxis with-
out any further cases of PJP.
Current guidelines vary without clear, consistent recom-
mendations for PJP prophylaxis in patients receiving
Bendamustine. Recent studies have prescribed PJP prophy-
laxis for patients with prolonged grade III/IV neutropenia
[23], based on local practice [24] or based on the CD4
count [19].There is increasing evidence that the majority of
patients will develop significant reductions in their CD4
counts post Bendamustine. Recent publications have
described PJP post Bendamustine treatment [15–18]. On
the basis of this series of cases and this increasing evidence
of CD4 T-cell suppression, we propose that the safest prac-
tice is to ensure that all patients receive PJP prophylaxis
from the beginning of treatment with Bendamustine.
Conclusion
The decision for PJP prophylaxis depends on a physician’s
evaluation of multiple variables, including corticosteroid,
duration, and dosage of other immunosuppressive therapy,
underlying pathology and comorbidities that may adversely
affect the immune system. The high rate of PJP infection
described in this article combined with the known impaired
T-cell function post Bendamustine treatment justifies con-
sidering all patients for PJP prophylaxis when they receive
Bendamustine treatment.
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